Findings

What do systematic reviews say?

77 questions · 79 findings · 25 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 3 · 3.8%Very low 8 · 10.1%Low 37 · 46.8%Moderate 20 · 25.3%High 11 · 13.9%

Triple therapy vs LABA/LAMA combination

Respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline (lower scores indicate better HRQoL) · stable COPD

Triple therapy leads to higher respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline… compared with LABA/LAMA combination (high certainty).

1 finding from 1 review

Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for… 2023 · Cochrane Headline outcomes only
OR 1.35 [1.26, 1.45]
3 studies · 14070 participants
High

Triple therapy vs LABA/LAMA combination

Symptoms of dyspnoea · stable COPD

Triple therapy probably leads to higher symptom score TDI, ≥ 1‐unit increase (lower scores indicate worse… compared with LABA/LAMA combination (moderate certainty).

1 finding from 1 review

Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for… 2023 · Cochrane Headline outcomes only
OR 1.33 [1.13, 1.57]
1 study · 3044 participants
Moderate

Mepolizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 369 participants
High

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1652 participants
High

Reslizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Reslizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Mepolizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

Benralizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2791 participants
High

Mepolizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

Macrolides vs placebo

Asthma symptoms · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 136 participants
Very low

Macrolides vs placebo

Asthma control · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 773 participants
Low

Intervention vs usual care

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · COPD and at least one other long‐term condition

1 finding from 1 review

Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Intervention vs usual care

Quality of life ‐ CAT · COPD and at least one other long‐term condition

1 finding from 1 review

Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
Low

Breathing exercises vs inactive control

Asthma control · adults with asthma

1 finding from 1 review

Breathing exercises for adults with asthma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 115 participants
Low

Breathing exercises vs inactive control

Nijmegen questionnaire · adults with asthma

1 finding from 1 review

Breathing exercises for adults with asthma 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 118 participants
Moderate

Mepolizumab 300 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 451 participants
Moderate

Benralizumab 10 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 680 participants
Moderate

Benralizumab 30 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1333 participants
Moderate

Benralizumab 100 mg vs placebo

Change in SGRQ total score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1433 participants
High

Benralizumab 100 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1351 participants
High